Sequoia China Leads $80M Pre-IPO Round In Chinese Biotech Firm

BrightGene Bio-Medical Technology Co., a Chinese biopharmaceutical company, has received RMB550 million (US$80.06 million) in a pre-IPO round of financing, led by Sequoia China and HighLight Capital, with participation from GF Qianhe Investment, according to a WeChat announcement released today. Currently, the company has several investors, including State Development Investment Corporation (SDIC), CICC Capital, Hong Kong-based […]

Sequoia China Leads $80M Pre-IPO Round In Chinese Biotech Firm appeared first on China Money Network.

Read the original article: China Money Network